| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 16 |
| 1 | PACLITAXEL | 16 |
| 2 | BEVACIZUMAB | 11 |
| 3 | RAMUCIRUMAB | 9 |
| 4 | DOCETAXEL | 7 |
| 5 | DOCETAXEL ANHYDROUS | 7 |
| 6 | NIVOLUMAB | 6 |
| 7 | REGORAFENIB | 5 |
| 8 | PAZOPANIB HYDROCHLORIDE | 4 |
| 9 | CYCLOPHOSPHAMIDE | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | RAMUCIRUMAB | 9 | 0.0014 |
| 1 | NALDEMEDINE | 1 | 0.0006 |
| 2 | REGORAFENIB | 5 | 0.0004 |
| 3 | LEMBOREXANT | 1 | 0.0003 |
| 4 | AMIVANTAMAB-VMJW | 1 | 0.0003 |
| 5 | VONOPRAZAN FUMARATE | 2 | 0.0002 |
| 6 | PACLITAXEL | 16 | 0.0002 |
| 7 | AFATINIB | 1 | 0.0002 |
| 8 | PAZOPANIB HYDROCHLORIDE | 4 | 0.0001 |
| 9 | ENFORTUMAB VEDOTIN | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 9 | 0.0014 |
| 1 | Microtubule Inhibitor [EPC] | 23 | 0.0001 |
| 2 | Orexin Receptor Antagonist [EPC] | 2 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 18 | 0.0001 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 3 | 0.0001 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 6 | 0.0001 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 11 | 0.0001 |
| 7 | Topoisomerase Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Alkylating Drug [EPC] | 3 | 0.0000 |
| 9 | Leukocyte Growth Factor [EPC] | 1 | 0.0000 |